42 - Maxwell Finland Lecture

Speaker(s)

• 

  Vance Fowler, Jr., MD, MHS

  Professor of Medicine
  Division of Infectious Diseases
  Duke University
  Durham, North Carolina

  Disclosure: Abbvie : Grant/Research Support (Status: Ongoing); Actavis : Grant/Research Support; Advanced Liquid Logics : Grant/Research Support; Affinergy : Consultant, Research Grant or Support; Affinium : Consultant; Allergan : Grant/Research Support; Ampliphi Biosciences : Consultant; Armata : Consultant (Status: Ongoing); Basilea : Consultant, Research Grant or Support; Bayer : Consultant, Consultant; C3J : Consultant; CARB-X : Consultant (Status: Ongoing); Cerexa : Consultant, Research Grant or Support; Contrafect : Consultant, Research Grant or Support; Cubist : Grant/Research Support; Debiopharm : Consultant; Destiny : Consultant; Durata : Consultant; Forest : Grant/Research Support; Genentech : Consultant, Research Grant or Support; ICBiome : Consultant (Status: Ongoing); Integrated Biotherapeutics : Consultant; Janssen : Consultant, Research Grant or Support; Karius : Grant/Research Support; Locus : Grant/Research Support; Medical Biosurfaces : Grant/Research Support; Medicines Co. : Consultant; Medimmune : Consultant, Research Grant or Support; Merck : Consultant, Research Grant or Support; NIH : Grant/Research Support; Novadigm : Consultant; Novartis : Consultant, Research Grant or Support; Pfizer : Grant/Research Support; Regeneron : Consultant, Research Grant or Support; Tetraphase : Consultant; Theravance : Consultant, Research Grant or Support; Valanbio : Board Member (Status: Ongoing), Other Financial or Material Support (Status: Ongoing), Stock options (Status: Ongoing); xBiotech : Consultant

CME Credits: Maximum of 0.5 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 0.5 hours of MOC Credit

No CPE Credits

Learning Objectives:

• describe the impact that a single project can have on improved patient outcome
• summarize the importance of clinical, bacterial, and host genetic factors in influencing the initiation and severity of infections caused by S. aureus

Presentations:

• 5:30pm – 6:00pm EDT

  Staphylococcus aureus: Lessons Learned from 20 Years with the Persistent Pathogen
  Vance G. Fowler, Jr., MD, MHS – Duke University